Results 41 to 50 of about 5,867,860 (378)

NKG2D and its ligands: one for all, all for one [PDF]

, 2018
The activating receptor NKG2D is peculiar in its capability to bind to numerous and highly diversified MHC class I-like self-molecules. These ligands are poorly expressed on normal cells but can be induced on damaged, transformed or infected cells, with ...
Cerboni, Cristina, Cippitelli, Marco, Fionda, Cinzia, Molfetta, Rosa, Paolini, Rossella, Santoni, Angela, Soriani, Alessandra, Zingoni, Alessandra   +7 more
core   +2 more sources

Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis. [PDF]

, 2017
Natural-killer receptor group 2, member D (NKG2D) is a well characterized natural killer (NK) cell activating receptor that recognizes several ligands poorly expressed on healthy cells but up-regulated upon stressing stimuli in the context of cancer or ...
Molfetta, R, Paolini, R., Quatrini, L, Santoni, A   +3 more
core   +5 more sources

Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model

Biomolecules, 2019
Here, we determined the anti-neoplastic actions of formononetin (FT) against multiple myeloma (MM) and elucidated its possible mode of action. It was observed that FT enhanced the apoptosis caused by bortezomib (Bor) and mitigated proliferation in MM ...
Chulwon Kim, Jong Hyun Lee, Jeong-Hyeon Ko, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Omar H.M. Shair, Gautam Sethi, Kwang Seok Ahn   +7 more
doaj   +1 more source

Retrospective evaluation of the use of the International Myeloma Working Group response criteria in dogs with secretory multiple myeloma

Journal of Veterinary Internal Medicine, 2021
Background Current recommendations for monitoring disease progression and response to treatment in humans with multiple myeloma include evaluation of serum paraprotein (M‐protein) concentration. Densitometry, species‐specific radial immunodiffusion (RID)
A Russell Moore, Adam Harris, Christina Jeffries, Paul R. Avery, Kate Vickery   +4 more
doaj   +1 more source

The non-coding RNA landscape of plasma cell dyscrasias [PDF]

, 2020
Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat.
Azab, Kareem A, et al,, Morelli, Eugenio, Rocca, Roberta   +3 more
core   +1 more source

Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma [PDF]

, 2016
Hepatocellular carcinoma (HCC) responds poorly to conventional systemic therapies. The first-in-class proteasome inhibitor bortezomib has been approved in clinical use for hematologic malignancies and has shown modest activity in solid tumors, including ...
Bogaerts, Eliene, Coucke, Céline, Devisscher, Lindsey, Geerts, Anja, Laukens, Debby, Libbrecht, Louis, Paridaens, Annelies, Raevens, Sarah, Van Steenkiste, Christophe, Van Vlierberghe, Hans, Vandewynckel, Yves-Paul, Vandierendonck, Aster, Verhelst, Xavier   +12 more
core   +2 more sources

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma

Haematologica, 2011
Background Isothiocyanates, a family of phytochemicals found in cruciferous vegetables, have cytotoxic effects against several types of tumor cells. Multiple myeloma is a fatal disease characterized by clonal proliferation of plasma cells in the bone ...
Jana Jakubikova, David Cervi, Melissa Ooi, Kihyun Kim, Sabikun Nahar, Steffen Klippel, Dana Cholujova, Merav Leiba, John F. Daley, Jake Delmore, Joseph Negri, Simona Blotta, Douglas W. McMillin, Teru Hideshima, Paul G. Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades   +17 more
doaj   +1 more source

The concentration and type of monoclonal protein and their impact on clinical severity in patients with symptomatic myeloma

Advanced Medical Journal, 2022
Background and objectives: Multiple Myeloma is a clonal plasma cell proliferation in the bone marrow that produces abnormal monoclonal proteins in serum and /or urine that leads to end-organ damage. We aimed to evaluate concentration, type of monoclonal
Ahmed Khudair Yassin, Najmaddin Salih Husen Khsohnaw, Sana Dlawar Jalal, Akram Mahmood Mohammed, Kawa Mohamedamin Hasan , Dana Ahmed Abdulla, Ameer Badi, Banaz Mubarak Safar, Basil Kadhim Abdulla, Rawand Polus Shamoon, Diveen Jalal Hussein, Nawsherwan Sadiq Mohammed, Kanar Jalal Karim, Abid Mohiaddin Hassen, Hisham Arf Getta, Rezhin Nawzad Rajab, Friad Hiwaizi Hiwaizi, Truska Awat Amin, Zeki Ali Mohamed, Ali Ibrahim Mohammed, Hameed Saeed, Parween Ismael, Alaa Alwan   +22 more
doaj   +1 more source

IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA?

Mediterranean Journal of Hematology and Infectious Diseases
The study of monoclonal serum proteins has led to the generation of two major theories: one proposing that individuals who had monoclonal proteins without any symptoms or evidence of end-organ damage have a benign condition; the other one suggesting ...
Ugo Testa, Giuseppe Leone, Elvira Pelosi, Germana Castelli, Valerio De Stefano   +4 more
doaj   +1 more source

Hepatocyte growth factor promotes migration of human myeloma cells

Haematologica, 2008
Multiple myeloma is characterized by the accumulation and dissemination of malignant plasma cells in the bone marrow. Cell migration is thought to be important for these events.
Randi Utne Holt, Unn-Merete Fagerli, Vadim Baykov, Torstein Baade Rø, Håkon Hov, Anders Waage, Anders Sundan, Magne Børset   +7 more
doaj   +1 more source